Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

- Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

- Saura, Christina, Oliveira, Mafalda, Hlauschek, Dominik, Zardavas, Dimitrios, Jallitsch-Halper, Anita, de la Peña, Lorena, Nuciforo, Paolo, Ballestrero, Alberto, Dubsky, Peter, Lombard, Janine M., Vuylsteke, Peter, Castaneda, Carlos A., Colleoni, Marco, Santos Borges, Giuliarno, Ciruelos, Eva, Fornier, Monica, Boer, Katalin, Bardia, Aditya, Wilson, Timothy R., Stout, Thomas J.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

- Ribi, Karin, Luo, Weixiu, Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Colleoni, Marco, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence

- Chirgwin, Jacquie H., Giobbie-Hurder, Anita, Forbes, John F., Neven, Patrick, Láng, István, Colleoni, Marco, Thürlimann, Beat, Coates, Alan S., Price, Karen N., Ejlertsen, Bent, Debled, Marc, Gelber, Richard D., Goldhirsch, Aron, Smith, Ian, Rabaglio, Manuela

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study

- Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

- Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial

- Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica